Search PubMed⌕ Search

Biomedical subjects

L Samochowiec

Publications and source records attributed to L Samochowiec.

80 records · Page 5Linked to original sources
PubMedDate not supplied

Experimental model of hyperlipidemia in rats.

Rats conceived for 14 days high-lipid diet containing coconut oil and cholesterol, given in various doses, separately or in combination, with or without cholic acid. Lipid serum fractions were assayed and lipoproteins were separated by agarose electrophoresis. The model of alimentary hyperlipidemia consisting of feeding rats for 14 days with a diet containing coconut oil (10 g/kg/day), cholesterol (4 g/kg/day) and cholic acid (0.2 g/kg/day) is proposed.

Animals↗
PubMedDate not supplied

A model of experimental atherosclerosis in pigs. Part I. Study on blood lipids and coagulation.

Pigs received for 24 weeks a high-lipid diet containing cholesterol and coconut oil. Blood lipid fractions were assayed, electrophoretic separation of lipoproteids was carried out, and tests for blood coagulation parameters (fibrinogen content, partial thromboplastin time, paracoagulation test, blood platelets aggregation) were carried out. In the blood serum of experimental animals the content of triglycerides, cholesterol, free fatty acids, lipid phosphorous and beta-lipoproteids gradually increased. A hyperlipidemia corresponding to type IV of Fredrickson was obtained. No parallel changes in the results of studies on blood coagulation parameters were observed.

Animals↗
PubMedDate not supplied

The effect of new furanochrome derivatives on circulatory system and respiratory activity of experimental animals.

Six new compounds of furanochromone group were tested for their acute toxicity (LD50), the effect on arterial blood pressure, respiratory activity of the cat, the effect on ECG and antiarrhythmic activity. All compounds produce a moderate hypotension. Protection against BaCl2-induced arrhythmia is offered by hydrochlorides of N-2-morpholino-etyl ester of alpha-2-methyl-8-methoxyfurano (3', 2' :6,7)-chromonoxy-5-butyric acid, 3, and of N, N-diethylaminoethyl ester of alpha-2-methyl-8-methoxyfurano-(3', 2' : 6,7)-chromonoxy-5-propionic acid, 4. These compounds show the weakest hypotensive activity. The most potent hypotensive action is produced by hydrochlorides of N,N-diethylaminoethyl ester of alpha-2-methyl-8-methoxyfurano (3', 2' : 6,7)-chromonoxy-5-butyric acid 1, and of N-/2-piperidinoethyl ester of alpha-2-methyl-8-methoxyfurano(3', 2' : 6,7)-chromonoxy-5-propionic acid, 5, (short-lasting action).

Animals↗
PubMedDate not supplied

Comparative pharmacokinetics and bioavailability of flavonoid glycosides of Ginkgo biloba after a single oral administration of three formulations to healthy volunteers.

Eighteen healthy volunteers received three different formulations of Ginkgo biloba: capsules (A) and drops (B) (delivered by Agon Pharma), and tablets (C) (Tebonin-Dr. W. Schwabe) in equal an quantity, orally as a single dose, at an interval of at least five days. The pharmacokinetic parameters of the most important flavonoid glycosides: quercetin, kaempferol and isorhamnetin were established. The bioavailability was estimated using capsules as a standard formulation. Only the time to reach the peak concentration (tmax) of quercetin, kaempforol and isorhamnetin administered in the form of capsules, was significantly prolonged as compared with drops and tablets. Area under the curve (AUC) was the largest for formulation B for all the evaluated flavonoid glycosides, however the differences were not statistically significant. It is concluded that the three formulations of Ginkgo biloba extract are bioequivalent.

Adolescent↗